RxDoctor Payments Data

Elizabeth Dale, MD

Ophthalmology · Bala Cynwyd, PANPI 1811218332

Payments from drug & device makers

$26,958in general payments, 2019–2025

Across 115 payments — averaging $234.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sight Sciences, Inc.$24K
  • AbbVie$709
  • Alcon$528
  • Glaukos Corporation$413
  • NEW World Medical,inc.$227
  • Aerie Pharmaceuticals, Inc.$143
  • plus $633 from 15 others

What the payments were for

  • Speaking & faculty fees$21,10078%
  • Travel & lodging$1,4936%
  • Food & beverage$4,30316%
  • Gifts$620%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$26,958 in reported general payments places this provider in the 85th percentile of 920 ophthalmology providers in Pennsylvania.

See all ophthalmology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$488,170
Medicare patients
846
Services billed
4,906

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost509$225,116
RhopressaNetarsudil Mesylate160$77,344
Alphagan PBrimonidine Tartrate216$59,554
Brimonidine Tartrate1,052$58,697
CombiganBrimonidine Tartrate/Timolol193$56,612
SimbrinzaBrinzolamide/Brimonidine Tart119$31,359
RestasisCyclosporine23$29,899
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol174$29,529
Travoprost177$29,420
VyzultaLatanoprostene Bunod76$27,924
RocklatanNetarsudil Mesylat/Latanoprost55$21,639
Prednisolone Acetate646$21,423
Latanoprost1,943$19,701
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat1,027$17,591
Dorzolamide-TimololDorzolamide/Timolol/Pf66$14,791

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Alphagan P, Combigan, Restasis$709$371,181941 claims
Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan$143$98,983215 claims
AlconSimbrinza$528$31,359119 claims
Bausch & Lomb Americas Inc.Vyzulta$58$27,92476 claims
NovartisTravatan Z$57$8,66124 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate$44$4,89722 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 920 ophthalmology providers in Pennsylvania.

Other ophthalmology in Bala Cynwyd

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →